期刊
TRANSLATIONAL NEURODEGENERATION
卷 9, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40035-020-00198-y
关键词
Frontotemporal dementia; Cerebrospinal fluid; Biomarkers; Proteomics; Antibody suspension bead array
资金
- Swedish FTD initiative - Schorling Family Foundation
- KTH Center for Applied Precision Medicine (KCAP) - Erling-Persson Family Foundation
- JPND Prefrontals Swedish Research Council (VR) [529-2014-7504]
- Swedish Research Council (VR) [2018-02754, 2015-02926]
- Swedish Brain Foundation
- Swedish Alzheimer Foundation
- Stockholm County Council ALF
- Karolinska Institutet Doctoral Funding
- StratNeuro, Swedish Demensfonden
- National Genomics Infrastructure in Stockholm/Uppsala - Science for Life Laboratory
- Knut and Alice Wallenberg Foundation
- Swedish Research Council
- Royal Institute of Technology
- Vinnova [2018-02754] Funding Source: Vinnova
- Swedish Research Council [2018-02754, 2015-02926] Funding Source: Swedish Research Council
Background: The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers. Methods: Antibody suspension bead arrays were used to analyse 328 proteins in CSF from patients with behavioural variant FTD (bvFTD, n = 16) and progressive primary aphasia (PPA, n = 13), as well as presymptomatic mutation carriers (PMC, n = 16) and non-carriers (NC, n = 8). A total of 492 antibodies were used to measure protein levels by direct labelling of the CSF samples. The findings were further examined in an independent cohort including 13 FTD patients, 79 patients with Alzheimer's disease and 18 healthy controls. Results: We found significantly altered protein levels in CSF from FTD patients compared to unaffected individuals (PMC and NC) for 26 proteins. The analysis show patterns of separation between unaffected individuals and FTD patients, especially for those with a clinical diagnosis of bvFTD. The most statistically significant differences in protein levels were found for VGF, TN-R, NPTXR, TMEM132D, PDYN and NF-M. Patients with FTD were found to have higher levels of TN-R and NF-M, and lower levels of VGF, NPTXR, TMEM132D and PDYN, compared to unaffected individuals. The main findings were reproduced in the independent cohort. Conclusion: In this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据